发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
BACKGROUND:The SELECT-D trial demonstrated reduction in recurrent venous thromboembolism (VTE) but increased bleeding with rivaroxaban compared to dalteparin for treatment of acute VTE in cancer patients, at 6 months. Uncertainty remains around optimal duration of anticoagulation. OBJECTIVES:To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 months PATIENTS/METHODS: In SELECT-D, after 6 months of trial treatment for VTE, patients with active cancer and residual deep vein thrombosis (RDVT) or index pulmonary embolism (PE) were eligible for randomisation to a further 6 months of rivaroxaban or placebo. Patients with no RDVT stopped anticoagulation. Primary outcome was VTE recurrence at 12 months. The second randomisation closed prematurely due to low recruitment when 92 of the planned 300 patients were recruited. RESULTS:92 of 136 eligible patients were randomised to rivaroxaban or placebo. The cumulative VTE recurrence after 6 months from the second randomisation, was 14% with placebo and 4% with rivaroxaban (Hazard Ratio 0.32; 95% CI 0.06-1.58). The major and clinically-relevant non-major bleeding rates were 0% and 0% with placebo; and 5% (95% CI 1-18%) and 4% (95% CI 1-17%) with rivaroxaban. In an exploratory analysis, 7 (15.2 %) of 46 placebo patients with RDVT or an index PE experienced recurrent VTE compared to none in the 35 patients in the RDVT-negative cohort (P=0.03). CONCLUSION:The SELECT-D trial was underpowered to detect a statistically significant reduction in recurrent VTE with extended anticoagulation. The absence of RDVT and/or index PE, defined a population at low risk of recurrence.
展开更多
最新影响因子:16.036 | 期刊ISSN:1538-7933 | CiteScore:3.8 |
出版周期:Monthly | 是否OA:YES | 出版年份:2003 |
期刊官方网址:http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1538-7836
自引率:7.70% | 研究方向:医学-外周血管病 |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
The mission of the new Journal of Thrombosis and Haemostasis will be to advance science related to the important medical problems of thrombosis, bleeding disorders and vascular biology through the diffusion and exchange of information and ideas within the international research community. The Journal publishes high quality, original research reports, state-of-the art reviews, invited commentary and debate on timely topics, letters and announcements. Editors invite both laboratory and clinical reports. The Journal of Thrombosis and Haemostasis is now available in print and online.
新一期《血栓与止血》杂志的使命是通过在国际研究领域内传播和交流信息和思想,促进与血栓形成、出血障碍和血管生物学等重要医学问题有关的科学。该杂志出版高质量的原创研究报告,最新的技术评论,邀请评论和辩论及时的主题,信件和公告。编辑邀请实验室和临床报告。《血栓与止血杂志》现已出版,并可在线阅读。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
HEMATOLOGY (血液学) 2区 PERIPHERAL VASCULAR DISEASE (外周血管病) 2区 |
14/71 7/65 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
243 | 226 | 17 |
引文计数(2018)
文献(2015-2017)
3861次引用
1015篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Hematology
|
#16/120
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
接受率: 中等(50%命中)
liting7111
研究方向:医药科学 血液系统 出血 凝血 血栓
影响因子:2.438
ISSN:0261-1929
研究方向:农林科学-兽医学
影响因子:3.025
ISSN:1094-7159
研究方向:医学-临床神经学
影响因子:4.169
ISSN:0264-410X
研究方向:医学-免疫学
影响因子:17.579
ISSN:0022-1007
研究方向:医学-免疫学
影响因子:5.274
ISSN:0971-5916
研究方向:医学-免疫学
影响因子:4.061
ISSN:2314-6745
研究方向:ENDOCRINOLOGY & METABOLISM-MEDICINE, RESEARCH & EX
影响因子:2.976
ISSN:0914-8779
研究方向:医学-内分泌学与代谢
影响因子:4.75
ISSN:0141-8955
研究方向:医学-内分泌学与代谢
影响因子:10.171
ISSN:1931-5244
研究方向:医学-医学:内科
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 投稿经验
(由下方点评分析获得,2人参与,9555人阅读)